Clinical trials: Hepatocellular Carcinoma, active
Bladder Carcinoma, Cervical Carcinoma
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
This exploratory study investigates how an imaging technique called 68Ga-FAPi-46 PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with cancer.
- Conditions
- Bladder Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Hematopoietic and Lymphoid Cell Neoplasm
- Trial name
- FAPI PET RDRC (NCT04459273)
- Testing
- Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the…
- Conditions
- Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, Advanced Bladder Carcinoma, Advanced Breast Carcinoma
- Trial name
- NCT05969860
- Testing
- Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 220 people
- Sponsor
- Mayo Clinic
Liver Neoplasms, Primary Liver Cancer
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
The goal of this observational study is to collect information on the use of the HistoSonics Edison System for the treatment of liver tumors.
- Conditions
- Liver Neoplasms, Primary Liver Cancer, Secondary Liver Cancer, Tumor Liver
- Trial name
- NCT06486454
- Testing
- HistoSonics Edison System
- Where
- 35 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- HistoSonics, Inc.
Bladder Carcinoma, Breast Carcinoma
The Vanguard Study: Testing a New Way to Screen for Cancer
The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial.
- Conditions
- Bladder Carcinoma, Breast Carcinoma, Colorectal Carcinoma, Esophageal Carcinoma
- Trial name
- NCT06995898
- Testing
- Biospecimen Collection, Device Usage, Electronic Health Record Review
- Where
- 46 sites in United States
- Volunteers
- 24,000 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer, Hepatocellular Carcinoma
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of…
- Trial name
- NCT07284121
- Testing
- Atezolizumab
- Where
- 92 sites in Austria, Belgium and 6 more
- Volunteers
- 700 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
Liver Cancer Registry Platform
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics…
- Trial name
- JADE (NCT04510740)
- Testing
- Physician's choice according to patient's needs.
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- iOMEDICO AG
Hepatocellular Carcinoma (HCC), Recurrent Hepatocellular Cancer
NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC
This study will evaluate nivolumab and ipilimumab, two immunotherapy medicines, given before repeat liver surgery in adults whose liver cancer (hepatocellular carcinoma) has returned within the liver after previous surgery.
- Trial name
- CA209-1594 (NCT07919717)
- Testing
- Nivolumab, Ipilimumab, Repeat Hepatectomy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shanghai Zhongshan Hospital
Pancreatic Cancer, Hepatocellular Cancer
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
A single-arm, interventional study combining Immunotherapy and propranolol with/without chemotherapy and propranolol 1. Pancreatic Cancer Durvalumab will be administered once every 4 weeks, in combination with gemcitabine +…
- Conditions
- Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer, Cholangiocarcinoma
- Trial name
- NCT05451043
- Testing
- Durvalumab, Gemcitabine, Nab paclitaxel
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- AHS Cancer Control Alberta
Combined Hepatocellular and Cholangiocarcinoma
A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
This is a single arm phase 2 study of Single Tremelimumab with Regular Interval Durvalumab (STRIDE) plus Gemcitabine and Cisplatin (GEMCIS) in locally advanced unresectable/metastatic combined hepatocellular-cholangiocarcinoma…
- Trial name
- NCT06855225
- Testing
- Tremelimumab, Durvalumab, Gemcitabine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Mehmet Akce
Hepatocellular Carcinoma, Liver Cancer
Characterizing Tumor Hypoxia With BOLD-MRI to Predict Y-90 Treatment Response
The purpose of this study is to find out whether a special type of magnetic resonance imaging ( MRI), called blood oxygen level-dependent (BOLD) MRI, can help measure how much oxygen is present in liver tumors.
- Trial name
- BOLDMRI (NCT07916376)
- Testing
- Blood oxygen level-dependent (BOLD) magnetic resonance imaging ( MRI)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hepatocellular Carcinoma (HCC), HCC - Hepatocellular Carcinoma
A Clinical Study Evaluating the Safety and Efficacy of Ivonescimab as Second-line Treatment in Patients With Advanced Hepatocellular Carcinoma
This trial will study the most common type of advanced liver cancer, hepatocellular carcinoma (HCC). Participants will be treated with ivonescimab, a drug targeting immune cells and blood vessels in tumors, which has proven…
- Conditions
- Hepatocellular Carcinoma (HCC), HCC - Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma (HCC)
- Trial name
- ANTHELA (NCT07917481)
- Testing
- Ivonescimab
- Volunteers
- 44 people
- Sponsor
- MedSIR
Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer
This phase III trial studies how well radiation therapy with protons works compared with photons in treating patients with liver cancer.
- Conditions
- Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Unresectable Hepatocellular Carcinoma
- Trial name
- NCT03186898
- Testing
- Proton Therapy, Photon Therapy
- Where
- 27 sites in United States
- Volunteers
- 116 people
- Sponsor
- NRG Oncology
Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
This phase I/II trial studies the side effects and how well nivolumab, fluorouracil, and interferon alpha 2b work for the treatment of fibrolamellar cancer (liver cell cancer) that cannot be removed by surgery (unresectable).
- Conditions
- Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT04380545
- Testing
- Fluorouracil, Nivolumab, Recombinant Interferon Alpha 2b-like Protein
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
This study is to evaluate the safety and tolerability to determine (i) the recommended Phase 2 dose (RP2D) of VMD-102 (Phase 1), and (ii) preliminary anti-tumor efficacy (Phase 2), in participants with advanced HCC, metastatic…
- Conditions
- Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC), Nonsmall Cell Lung Cancer
- Trial name
- SPKTAHC (NCT07636785)
- Testing
- VMD-102
- Where
- 2 sites in United States
- Volunteers
- 111 people
- Sponsor
- VM Discovery, Inc.
Hepatocellular Carcinoma
PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCC
This is a single-arm, open-label, phase II clinical trial. Patients with unresectable hepatocellular carcinoma (HCC) who are eligible for lenvatinib treatment will receive partial transarterial chemoembolization (TACE) targeting…
- Trial name
- Pearl (NCT07827807)
- Testing
- Lenvatinib, Partial transarterial chemoembolization (TACE)
- Volunteers
- 40 people
- Sponsor
- Chang Gung Memorial Hospital
Hepatocellular Cancer, Liver Cancer
Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy and safety of BGB-B2033 monotherapy in adults with hepatocellular carcinoma who have previously been treated with anti-programmed cell death protein 1 (PD-1)/programmed…
- Conditions
- Hepatocellular Cancer, Liver Cancer, Hepatocellular Carcinoma
- Trial name
- NCT07911683
- Testing
- BGB-B2033
- Volunteers
- 100 people
- Sponsor
- BeOne Medicines
Resectable Hepatocellular Carcinoma (HCC)
Integration of Imaging, Molecular, Pathological, and Clinical Outcome Data in Hepatocellular Carcinoma.
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death globally. Surgical resection is the mainstay of curative-intent treatment, but the 5-year postoperative recurrence rate can be as high as 70%.
- Trial name
- IMPACT (NCT07912853)
- Testing
- Resection
- Where
- China
- Volunteers
- 380 people
- Sponsor
- West China Hospital
Magnetic Resonance Imaging, Hepatocellular Carcinoma
Improving Hepatocellular Carcinoma Screening
This is a monocentric, single blind, interventional, single arm study. It is designed to compare the rates of detection of hepatocellular carcinoma (HCC) by ultrasound (US) used in clinical routine vs.
- Conditions
- Magnetic Resonance Imaging, Hepatocellular Carcinoma, Screening, Contrast-enhanced US
- Trial name
- AMRIK (NCT05828446)
- Testing
- MRI
- Where
- Switzerland
- Volunteers
- 330 people
- Sponsor
- Naik Vietti Violi
Hepatocellular Carcinoma, Cholangiocarcinoma
Targeted Navigation in Hepatocellular Carcinoma (HCC)
The investigators are trying to learn more about the personal perceptions and experiences regarding the needs of patients with liver cancer to help improve the care of all patients.
- Conditions
- Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatobiliary Cancer
- Trial name
- NCT06260943
- Testing
- Target Navigation Pilot Program
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- University of Miami
Barcelona Clinic Liver Cancer (BCLC) Stage A, B or C HCC, Hepatocellular Carcinoma (HCC)
DNP-MRSI of HCC Metabolism to Predict Therapeutic Response
This proposal describes a non-therapeutic diagnostic clinical trial to estimate the ability of DNP-MRS imaging of hyperpolarized 1-13C-pyruvate uptake and metabolism to predict response following LRT with TACE/TARE/Microwave…
- Trial name
- NCT07807475
- Testing
- Hyperpolarized 1-13C -Pyruvate
- Where
- United States
- Volunteers
- 232 people
- Sponsor
- Abramson Cancer Center at Penn Medicine